| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 35 | 2020 | 5319 | 3.080 |
Why?
|
| Lung Neoplasms | 53 | 2020 | 11538 | 2.980 |
Why?
|
| Endonucleases | 6 | 2011 | 178 | 1.150 |
Why?
|
| Antineoplastic Agents | 20 | 2017 | 14289 | 0.930 |
Why?
|
| Molecular Targeted Therapy | 8 | 2016 | 2330 | 0.930 |
Why?
|
| Small Cell Lung Carcinoma | 4 | 2020 | 406 | 0.850 |
Why?
|
| Biological Therapy | 2 | 2012 | 58 | 0.820 |
Why?
|
| Mesothelioma | 4 | 2020 | 544 | 0.770 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2020 | 15862 | 0.730 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 3 | 2019 | 245 | 0.690 |
Why?
|
| Pleural Neoplasms | 3 | 2008 | 470 | 0.670 |
Why?
|
| Carboplatin | 5 | 2019 | 823 | 0.670 |
Why?
|
| Carcinoma, Small Cell | 4 | 2007 | 408 | 0.660 |
Why?
|
| Paclitaxel | 6 | 2019 | 1996 | 0.620 |
Why?
|
| Pemetrexed | 6 | 2019 | 102 | 0.610 |
Why?
|
| Glutamates | 3 | 2013 | 130 | 0.610 |
Why?
|
| Guanine | 3 | 2013 | 151 | 0.600 |
Why?
|
| Neoplasm Proteins | 4 | 2014 | 3230 | 0.590 |
Why?
|
| Oncogenes | 1 | 2019 | 673 | 0.550 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2011 | 1823 | 0.550 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2020 | 3251 | 0.550 |
Why?
|
| Folic Acid Antagonists | 2 | 2013 | 45 | 0.540 |
Why?
|
| DNA-Binding Proteins | 8 | 2013 | 4821 | 0.540 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 252 | 0.530 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 348 | 0.520 |
Why?
|
| Evidence-Based Medicine | 3 | 2018 | 1085 | 0.510 |
Why?
|
| Artificial Intelligence | 1 | 2018 | 388 | 0.490 |
Why?
|
| Cancer Pain | 1 | 2019 | 312 | 0.470 |
Why?
|
| Biological Factors | 1 | 2013 | 45 | 0.470 |
Why?
|
| Clinical Trials as Topic | 10 | 2018 | 3719 | 0.460 |
Why?
|
| Pain Management | 1 | 2019 | 668 | 0.450 |
Why?
|
| Albumins | 1 | 2014 | 258 | 0.440 |
Why?
|
| Biomarkers, Tumor | 8 | 2019 | 10331 | 0.440 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 5 | 2011 | 29 | 0.430 |
Why?
|
| Fatigue | 1 | 2019 | 1239 | 0.430 |
Why?
|
| Neoplasm Staging | 16 | 2020 | 13658 | 0.380 |
Why?
|
| Neoplasms | 13 | 2018 | 15193 | 0.380 |
Why?
|
| Humans | 74 | 2020 | 261506 | 0.380 |
Why?
|
| Deoxycytidine | 5 | 2011 | 1353 | 0.370 |
Why?
|
| Medical Oncology | 1 | 2018 | 1423 | 0.360 |
Why?
|
| Quinazolines | 4 | 2012 | 923 | 0.350 |
Why?
|
| Quality of Life | 2 | 2020 | 4532 | 0.320 |
Why?
|
| Aged | 32 | 2020 | 70117 | 0.310 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2007 | 61 | 0.310 |
Why?
|
| Taxoids | 4 | 2008 | 967 | 0.300 |
Why?
|
| Camptothecin | 2 | 2007 | 517 | 0.300 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2014 | 3890 | 0.300 |
Why?
|
| Etoposide | 2 | 2006 | 870 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2020 | 10035 | 0.290 |
Why?
|
| ErbB Receptors | 7 | 2016 | 2295 | 0.270 |
Why?
|
| Benzamides | 1 | 2011 | 1832 | 0.260 |
Why?
|
| Maximum Tolerated Dose | 7 | 2012 | 1290 | 0.260 |
Why?
|
| Middle Aged | 31 | 2020 | 86204 | 0.250 |
Why?
|
| Morpholines | 1 | 2006 | 289 | 0.250 |
Why?
|
| Male | 33 | 2020 | 123000 | 0.240 |
Why?
|
| Polycomb Repressive Complex 2 | 2 | 2015 | 160 | 0.240 |
Why?
|
| Female | 35 | 2020 | 141928 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2014 | 5437 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2015 | 2594 | 0.220 |
Why?
|
| Cisplatin | 5 | 2020 | 2432 | 0.220 |
Why?
|
| Neoplasm Metastasis | 6 | 2020 | 5112 | 0.210 |
Why?
|
| DNA Repair | 2 | 2007 | 1872 | 0.210 |
Why?
|
| Vinblastine | 1 | 2003 | 453 | 0.210 |
Why?
|
| Sulfonamides | 1 | 2011 | 1823 | 0.210 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 423 | 0.200 |
Why?
|
| Disease-Free Survival | 4 | 2019 | 10001 | 0.200 |
Why?
|
| Survival Analysis | 8 | 2019 | 9180 | 0.200 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2019 | 612 | 0.200 |
Why?
|
| Cancer Vaccines | 2 | 2018 | 697 | 0.190 |
Why?
|
| ras Proteins | 3 | 2015 | 770 | 0.190 |
Why?
|
| Dendritic Cells | 2 | 2018 | 1085 | 0.180 |
Why?
|
| Prognosis | 11 | 2019 | 21713 | 0.180 |
Why?
|
| Aged, 80 and over | 12 | 2019 | 29902 | 0.170 |
Why?
|
| DNA Damage | 1 | 2007 | 1954 | 0.170 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 4320 | 0.170 |
Why?
|
| Histone Deacetylases | 2 | 2019 | 365 | 0.170 |
Why?
|
| Immunotherapy | 4 | 2020 | 3341 | 0.170 |
Why?
|
| Adult | 24 | 2020 | 77950 | 0.170 |
Why?
|
| Survival Rate | 5 | 2019 | 12221 | 0.170 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2003 | 852 | 0.160 |
Why?
|
| Adenocarcinoma | 6 | 2015 | 7789 | 0.160 |
Why?
|
| Symptom Assessment | 1 | 2020 | 267 | 0.160 |
Why?
|
| Bevacizumab | 2 | 2019 | 938 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 2 | 2014 | 543 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 2 | 2007 | 4367 | 0.150 |
Why?
|
| Treatment Outcome | 14 | 2020 | 32848 | 0.150 |
Why?
|
| Gene Expression | 2 | 2019 | 3570 | 0.140 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 538 | 0.140 |
Why?
|
| Genes, BRCA1 | 2 | 2010 | 387 | 0.140 |
Why?
|
| Receptor, ErbB-2 | 1 | 2006 | 2518 | 0.140 |
Why?
|
| Drug Administration Schedule | 5 | 2011 | 3472 | 0.140 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 6009 | 0.140 |
Why?
|
| Maleimides | 1 | 2015 | 22 | 0.140 |
Why?
|
| Cell Proliferation | 2 | 2012 | 7226 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 4938 | 0.130 |
Why?
|
| Hepatitis B, Chronic | 1 | 2017 | 137 | 0.130 |
Why?
|
| Psychometrics | 1 | 2020 | 937 | 0.130 |
Why?
|
| Brain Neoplasms | 3 | 2007 | 4849 | 0.130 |
Why?
|
| Hepatitis B virus | 1 | 2017 | 217 | 0.130 |
Why?
|
| Cranial Irradiation | 3 | 2007 | 315 | 0.130 |
Why?
|
| Precision Medicine | 2 | 2013 | 1154 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 524 | 0.130 |
Why?
|
| Ipilimumab | 1 | 2019 | 710 | 0.130 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 161 | 0.130 |
Why?
|
| Chemoradiotherapy | 2 | 2020 | 1946 | 0.130 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2015 | 146 | 0.120 |
Why?
|
| Mutation | 5 | 2016 | 15179 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2008 | 5178 | 0.120 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2013 | 22 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 1249 | 0.120 |
Why?
|
| Half-Life | 2 | 2011 | 259 | 0.110 |
Why?
|
| Platinum Compounds | 1 | 2013 | 131 | 0.110 |
Why?
|
| Alleles | 1 | 2019 | 2437 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2018 | 2292 | 0.110 |
Why?
|
| Refractometry | 1 | 2012 | 11 | 0.110 |
Why?
|
| Apoptosis | 1 | 2007 | 7591 | 0.110 |
Why?
|
| Genes, ras | 1 | 2015 | 667 | 0.110 |
Why?
|
| Pyridines | 2 | 2020 | 1244 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2014 | 447 | 0.110 |
Why?
|
| Vaccination | 1 | 2018 | 1123 | 0.110 |
Why?
|
| Cell Line, Tumor | 4 | 2019 | 14551 | 0.110 |
Why?
|
| Biosensing Techniques | 1 | 2012 | 75 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2015 | 4757 | 0.100 |
Why?
|
| Molecular Typing | 1 | 2012 | 55 | 0.100 |
Why?
|
| Immunoassay | 1 | 2012 | 216 | 0.100 |
Why?
|
| Thiophenes | 1 | 2012 | 148 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2015 | 1678 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 848 | 0.100 |
Why?
|
| Combined Modality Therapy | 5 | 2019 | 8865 | 0.100 |
Why?
|
| Disease Progression | 4 | 2017 | 6682 | 0.100 |
Why?
|
| Ceramides | 1 | 2011 | 95 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 661 | 0.100 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2014 | 565 | 0.100 |
Why?
|
| Pyrazoles | 2 | 2020 | 1471 | 0.100 |
Why?
|
| Patient Selection | 1 | 2018 | 2055 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 1586 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2018 | 929 | 0.090 |
Why?
|
| Oligonucleotides | 1 | 2011 | 227 | 0.090 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2011 | 248 | 0.090 |
Why?
|
| Mediastinum | 1 | 2012 | 268 | 0.090 |
Why?
|
| Tubulin | 1 | 2010 | 169 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2017 | 1230 | 0.090 |
Why?
|
| Chromatography, Liquid | 1 | 2011 | 342 | 0.090 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 7548 | 0.090 |
Why?
|
| Transcription Factors | 3 | 2013 | 5270 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 1866 | 0.090 |
Why?
|
| Quinolines | 1 | 2012 | 383 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 2315 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2011 | 368 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 4988 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 3 | 2020 | 4975 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2008 | 4892 | 0.080 |
Why?
|
| Salvage Therapy | 3 | 2018 | 2054 | 0.080 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 101 | 0.080 |
Why?
|
| Polyglutamic Acid | 1 | 2007 | 47 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 1143 | 0.070 |
Why?
|
| Comorbidity | 2 | 2017 | 2352 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2010 | 5159 | 0.070 |
Why?
|
| Doxorubicin | 2 | 2011 | 3005 | 0.070 |
Why?
|
| Smoking | 2 | 2007 | 2440 | 0.070 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2006 | 57 | 0.070 |
Why?
|
| Pneumonectomy | 1 | 2012 | 831 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 3552 | 0.070 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2006 | 116 | 0.070 |
Why?
|
| Biological Availability | 1 | 2006 | 214 | 0.070 |
Why?
|
| Biological Transport | 1 | 2007 | 597 | 0.070 |
Why?
|
| Forecasting | 1 | 2009 | 694 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2013 | 6207 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2006 | 1544 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 573 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 1870 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 552 | 0.060 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2006 | 156 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2009 | 1113 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2007 | 665 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2007 | 1313 | 0.060 |
Why?
|
| Time Factors | 4 | 2017 | 12926 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 1331 | 0.060 |
Why?
|
| Teniposide | 1 | 2003 | 4 | 0.060 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2016 | 388 | 0.060 |
Why?
|
| Podophyllotoxin | 1 | 2003 | 63 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 1303 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4557 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2010 | 2403 | 0.050 |
Why?
|
| Animals | 4 | 2015 | 59536 | 0.050 |
Why?
|
| Incidence | 2 | 2017 | 5673 | 0.050 |
Why?
|
| Transfection | 2 | 2018 | 2944 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2020 | 37905 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2007 | 2231 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 2508 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 1299 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 1450 | 0.050 |
Why?
|
| Microtubules | 1 | 2003 | 270 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 14889 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2007 | 3536 | 0.050 |
Why?
|
| Glucose | 1 | 2007 | 1248 | 0.050 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 598 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2010 | 2488 | 0.050 |
Why?
|
| Young Adult | 3 | 2019 | 21445 | 0.050 |
Why?
|
| Organoplatinum Compounds | 1 | 2003 | 702 | 0.050 |
Why?
|
| Azepines | 1 | 2020 | 124 | 0.040 |
Why?
|
| Algorithms | 1 | 2011 | 3890 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2003 | 749 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2017 | 9244 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2007 | 3842 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2014 | 11965 | 0.040 |
Why?
|
| CD4 Antigens | 1 | 1999 | 170 | 0.040 |
Why?
|
| Pancytopenia | 1 | 1999 | 120 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2012 | 700 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2020 | 370 | 0.040 |
Why?
|
| Pyrimidines | 2 | 2020 | 3518 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 1999 | 593 | 0.040 |
Why?
|
| Population Groups | 1 | 2016 | 42 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 669 | 0.030 |
Why?
|
| Liver Failure | 1 | 2017 | 140 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 3976 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 495 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 756 | 0.030 |
Why?
|
| Age Distribution | 1 | 2017 | 698 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2003 | 1248 | 0.030 |
Why?
|
| Adolescent | 2 | 2016 | 31252 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 1999 | 943 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 249 | 0.030 |
Why?
|
| Indoles | 1 | 2020 | 1009 | 0.030 |
Why?
|
| Recurrence | 2 | 2013 | 4758 | 0.030 |
Why?
|
| Bystander Effect | 1 | 2013 | 23 | 0.030 |
Why?
|
| HIV-1 | 1 | 1999 | 653 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 733 | 0.030 |
Why?
|
| CD40 Ligand | 1 | 2013 | 115 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 1022 | 0.030 |
Why?
|
| Miniaturization | 1 | 2012 | 47 | 0.030 |
Why?
|
| K562 Cells | 1 | 2013 | 338 | 0.030 |
Why?
|
| Silicon | 1 | 2012 | 48 | 0.030 |
Why?
|
| Crystallization | 1 | 2012 | 132 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2013 | 272 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2012 | 159 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 4298 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2013 | 408 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2012 | 329 | 0.030 |
Why?
|
| Transgenes | 1 | 2013 | 557 | 0.030 |
Why?
|
| Palliative Care | 1 | 2003 | 2037 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2015 | 783 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2012 | 429 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 875 | 0.020 |
Why?
|
| Tretinoin | 1 | 2013 | 623 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 7551 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 1183 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 4654 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2019 | 1330 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 7702 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2015 | 1245 | 0.020 |
Why?
|
| Cell Death | 1 | 2012 | 671 | 0.020 |
Why?
|
| United States | 1 | 2006 | 15433 | 0.020 |
Why?
|
| Equipment Design | 1 | 2012 | 1204 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 1688 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2016 | 1589 | 0.020 |
Why?
|
| Acetylation | 1 | 2009 | 508 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2015 | 4307 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 4804 | 0.020 |
Why?
|
| Solubility | 1 | 2007 | 242 | 0.020 |
Why?
|
| Lactones | 1 | 2007 | 94 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2015 | 1616 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 1506 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2009 | 442 | 0.020 |
Why?
|
| HIV Infections | 1 | 1999 | 2134 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2006 | 242 | 0.020 |
Why?
|
| Cetuximab | 1 | 2007 | 472 | 0.020 |
Why?
|
| Urea | 1 | 2006 | 290 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 2004 | 159 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2019 | 12873 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 6869 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 2054 | 0.020 |
Why?
|
| Exanthema | 1 | 2006 | 211 | 0.020 |
Why?
|
| Heart | 1 | 2009 | 1223 | 0.010 |
Why?
|
| Diarrhea | 1 | 2006 | 686 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2013 | 4078 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 4844 | 0.010 |
Why?
|
| Lung | 1 | 2013 | 3151 | 0.010 |
Why?
|
| Thiazoles | 1 | 2006 | 726 | 0.010 |
Why?
|
| Histones | 1 | 2009 | 1466 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 589 | 0.010 |
Why?
|
| Skin | 1 | 2007 | 1259 | 0.010 |
Why?
|
| Biomarkers | 1 | 2011 | 5047 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 1999 | 32 | 0.010 |
Why?
|
| Receptors, CCR5 | 1 | 1999 | 52 | 0.010 |
Why?
|
| Sex Factors | 1 | 2004 | 2139 | 0.010 |
Why?
|
| Biopsy | 1 | 2007 | 3443 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1999 | 173 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 1390 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 2173 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1999 | 144 | 0.010 |
Why?
|
| Clone Cells | 1 | 1999 | 555 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 1999 | 269 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1999 | 362 | 0.010 |
Why?
|
| Age Factors | 1 | 2004 | 5377 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 34495 | 0.010 |
Why?
|